Novo Nordisk said stockpiling related to COVID-19 led to a double-digit percentage increase in the company’s sales in the first quarter of this year.

The Danish drugmaker said sales grew by 14 percent to $4.9 billion in the first three months of the year, with increased prescriptions and wholesaler inventories. 

Adjusting for the stockpiling, the company estimated sales growth would have been just 7 percent.